Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


KAI Pharmaceuticals Inc.

Division of Amgen Inc.

Latest From KAI Pharmaceuticals Inc.

Pionyr Maps Tumor Microenvironment, Plans 'Surgical' Strikes

Emerging Company Profile: Pionyr Immunotherapeutics exec who once led early development for Merck's PD-1 inhibitor Keytruda explains the San Francisco start-up's approach to rebalancing the tumor's microenvironment in order to improve outcomes.

StartUps and SMEs ImmunoOncology

Rival For Opdivo As Keytruda Launches For NSCLC In Japan At Same Daily Price

Opdivo has a new rival in the lung cancer setting in Japan following the reimbursement and launch of Keytruda at the same daily price.

Japan Policy

Japan Keytruda NSCLC Approval Sets Stage For Opdivo Showdown

Keytruda has been approved in Japan for lung cancer, including first-line use, in a batch of new regulatory clearances that also include the country's first prescription drug for irritable bowel syndrome with constipation.

Japan Approvals

Amgen Gets Parsabiv CRL, Gives No Clues As To Why

FDA issued a complete response letter for the Sensipar follow-on, and Amgen declined to provide any details about the reason why or timeline for resubmission.

BioPharmaceutical Commercial
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Drug Delivery
      • Transdermal
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Amgen Inc.
  • Senior Management
  • Natalie Holles, VP, Bus. Dev.
    Gregory Bell, MD, SVP, Dev. & CMO
  • Contact Info
  • KAI Pharmaceuticals Inc.
    Phone: (650) 244-1100
    270 Littlefield Ave.
    S. San Francisco, CA 94080